Anne Arundel Medical Center has appointed Dr. Barry R. Meisenberg, the former head of the hematology-oncology division at the University of Maryland's Cancer Center, as the new director of its Geaton and JoAnn DeCesaris Cancer Institute.
Martin L. Doordan, president and CEO of Anne Arundel Health System, said the hiring of Meisenberg reinforces the medical system's commitment to excellence in oncology care.
"Recruiting a physician of national caliber such as Dr. Meisenberg was only possible because of the overall excellence of our programs, talent of our medical and nursing staffs and investment in our facilities," Doordan said.
While at Maryland, Meisenberg helped guide the university's Marlene & Stewart Greenebaum Cancer Center to national prominence.
"The Geaton and JoAnn DeCesaris Cancer Institute has a core of talented and experienced physicians, nurses and other professionals representing a strong foundation on which to build one of Maryland's leading oncology programs," Meisenberg said. "In order to match the increasing complexity of the diseases we battle, we must continue to expand our screening, prevention and treatment offerings, taking advantage of the latest in medical research. We will remain a patient-centered program while incorporating exciting new treatment possibilities for patients with cancer and related diseases."
Meisenberg succeeds Dr. Stanley P. Watkins, who is widely credited with building the AAMC DeCesaris Cancer Institute to its current regional prominence.